UBS analyst Michael Yee has moved Biogen up to a Buy recommendation from Neutral and increased the firm's price target to $225 from $185 in a note released on Wednesday. The upgrade is driven by what UBS characterizes as a concentrated sequence of clinical and data milestones over the next 12 to 15 months that the market may not have fully priced.
Yee notes that Biogen appears discounted versus large-cap peers, trading at about 11 times estimated 2027 earnings compared with a group mean of 15 times. He describes the shares as an "underowned, out-of-favor stock" and frames the valuation gap as a key part of the bullish thesis.
UBS quantifies the risk-reward as approximately 25% to 50% upside from current levels against roughly 20% downside.
The UBS bullish case is anchored by four primary catalysts:
- BIIB080 tau data expected this summer. UBS acknowledges the trial was downsized and that statistical significance is unlikely, but it points to encouraging PET tau reduction trends and assigns an asymmetrical outcome expectation - upside skewed more than downside. UBS frames the potential move as up 10-25% versus a downside of maybe 5-10% based on these trends.
- Phase III litifilimab data in systemic lupus erythematosus (SLE) due in the fourth quarter. UBS treats this as a more material catalyst, assigning a 65% probability of success and projecting peak sales north of $1 billion in that indication alone. The firm estimates positive Phase III results could propel the stock 20% or more.
- Additional data for cutaneous lupus erythematosus expected mid-2027. UBS describes this indication as "wide open with no approved therapies," highlighting the potential commercial opportunity if data are positive.
- Phase III felzartamab data in antibody-mediated rejection following kidney transplant due in the first half of 2027. UBS assigns a 55% to 60% probability of success to this program.
To reach its $225 target, UBS applies a 14 times price-to-earnings multiple to Biogen's 2027 estimated earnings of $16.53 per share. That calculation supports the firms revised valuation and underpins the upgrade.
Below are the key takeaways and considerations stemming from UBSs note, focused on valuation, the timing of near-term readouts, and the range of outcomes UBS models for Biogens pipeline catalysts.